Tyler York, MD
Clinical Instructor, Surgery - Abdominal Transplantation
Clinical Focus
- General Surgery
- Abdominal Transplant Surgery
- Liver Transplant
- Kidney Transplant
- Multivisceral transplant
- Machine perfusion
- Surgical outcomes research
- Hepatobiliary Disease
Professional Education
-
Board Certification: American Board of Surgery, General Surgery (2025)
-
Residency: Rutgers Robert Wood Johnson General Surgery Residency (2025) NJ
-
Residency: University of Pennsylvania (2022) PA
-
Medical Education: Royal College of Surgeons In Ireland School of Medicine (2018) Ireland
All Publications
-
In policy and in practice: expedited placement and allocation out of sequence in liver transplantation.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
2026
Abstract
United States liver transplant policy debate has conflated two distinct mechanisms: Expedited Placement (OPTN Policy 9.10), a formal route for late turndowns when in-sequence offering risks non-utilization, and allocation out-of-sequence (AOOS), informal organ procurement organization (OPO) outreach beyond the match-run. Linking Standard Transplant Analysis and Research files to the Potential Transplant Recipient database (March 2021-December 2025), we classified 61,626 match-runs (41,638 transplanted) by pathway: in-sequence <50 offers (n=32,165), in-sequence ≥50 (n=3,450), AOOS (n=5,486), and Expedited Placement (n=537). AOOS rose 132% while Expedited Placement grew 6% and was absent in 12 of 55 OPOs. Before acceptance, a median 10 centers were contacted per AOOS graft versus 6 in-sequence, and AOOS refusals far more often covered entire waitlists (median 28 patients declined per donor versus 2). Most in-sequence acceptances occurred before donor cross-clamp (median 17.0 hours prior), whereas AOOS and Expedited Placement acceptances occurred after (0.15 and 2.42 hours). AOOS transplants occurred more frequently at centers with higher in-sequence acceptance of hard-to-place organs (Spearman 0.866), with comparable survival. These patterns are consistent with AOOS occurring after in-sequence placement has stalled, rather than as early bypass of in-sequence candidates; the circumstance Expedited Placement was designed for.
View details for DOI 10.1016/j.ajt.2026.09.022
View details for PubMedID 42763043
-
PREDICTING 90-DAY GRAFT LOSS IN PEDIATRIC LIVER RECIPIENTS USING MACHINE LEARNING MODEL BASED ON STABILITY-SELECTED PRE-TRANSPLANT FACTORS
LIPPINCOTT WILLIAMS & WILKINS. 2026: 177-178
View details for Web of Science ID 001769826101090
-
Initial Experience with Routine Post-Operative Contrast Enhanced Ultrasound Following Pediatric Whole and Partial Deceased Donor Liver Transplant
ELSEVIER SCIENCE INC. 2026
View details for Web of Science ID 001684522300010
-
When Offers Descend: Pathway, Timing, and Outcomes in Liver Transplantation
ELSEVIER SCIENCE INC. 2026
View details for Web of Science ID 001684210000071
-
Machine Learning Model for Predicting 90-Day Graft Failure in Pediatric Liver Transplantation Using Stability-Selected Pre-Transplant Factors
ELSEVIER SCIENCE INC. 2026
View details for Web of Science ID 001684210000073
-
Approaches to Mitigate Longer Cold Ischemic Times and Increased Rates of Delayed Graft Function Associated With the Revised Kidney Allocation System
CURRENT TRANSPLANTATION REPORTS
2023; 10 (4): 275-281
View details for DOI 10.1007/s40472-023-00419-z
View details for Web of Science ID 001103890000001
-
Accurate Identification of Mucinous Pancreatic Cystic Lesions Using Small-Volume Analytes.
The Journal of surgical research
2022
Abstract
INTRODUCTION: The accurate identification of mucinous pancreatic cystic lesions (PCLs) is paramount for cancer risk stratification. Cyst fluid carcinoembryonic antigen (CEA), the only routinely used test, requires high volumes and has low sensitivity. We aimed to compare the performance of two investigational small-volume biomarkers, glucose and the protease gastricsin, to CEA for PCL classification.METHODS: We obtained cyst fluid samples from 81 patients with pathologically confirmed PCLs from four institutions between 2003 and 2016. Gastricsin activity was measured using an internally quenched fluorescent substrate. Glucose levels were measured with a standard glucometer. CEA levels were obtained from the medical record. Models using Classification and Regression Trees were created to predict mucinous status. Model performance was evaluated using nested cross-validation.RESULTS: Gastricsin activity, CEA, and glucose levels from patients with mucinous (n=50) and nonmucinous (n=31) PCLs were analyzed. Area under the curve (AUC) was similar for individual classifiers (gastricsin volume normalized [GVN] 0.88; gastricsin protein concentration normalized [GPN] 0.95; glucose 0.83; CEA 0.84). The combination of two classifiers did not significantly improve AUC, with CEA+GVN (0.88) performing similarly to CEA+GPN (0.95), GVN+glucose (0.87), GPN+glucose (0.95), and CEA+glucose (0.84). The three-analyte combination performed similarly to single and dual classifiers (GPN+glucose+CEA AUC 0.95; GVN+glucose+CEA AUC 0.87). After multiple comparison corrections, there were no significant differences between the individual, dual, and triple classifiers.CONCLUSIONS: Gastricsin and glucose performed similarly to CEA and required <5% of the volume required for CEA; these classifiers may be useful in patients with limited cyst fluid. Future multicenter prospective studies are needed to validate and compare these novel small-volume biomarkers.
View details for DOI 10.1016/j.jss.2022.08.014
View details for PubMedID 36369049